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until termination (MCO termination, change to non-
statin antihyperlipidemic, or end of observation period). 
RESULTS: Of 4,964 enrollees who received ≥2 statin 
prescriptions, 540 (11%) patients were classiﬁed as 
secondary prevention and 4424 (89%) primary preven-
tion. The mean CMG while actively taking statin was
20.5% (SD 21.5, median 12.7) for the primary group and
21.9% (SD 22.7, median 13.3) for the secondary group
(p = 0.34). The mean CMG until termination was 29.2%
(SD 26.9, median 20.1) and 31.5% (SD 27.3, median
24.6) for the primary and secondary groups respectively
(p = 0.06). Additional analyses will measure the effect 
of patient demographics, copayments, and prescriber 
specialty. 
CONCLUSIONS: Compliance with statins was similar
and sub-optimal in primary and secondary prevention
populations. These data demonstrate that patients exhibit
poor compliance while actively taking therapy and 
contribute to future risk by discontinuing therapy at
undesirable rates. While universal compliance with pre-
scribed therapy for all patients indicated for therapy is a
desirable goal, incremental efforts should aim at improv-
ing compliance in those populations who are the most
likely to beneﬁt from their use.
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OBJECTIVE: The National Cholesterol Education
Program recently recommended the implementation of
interventions to improve compliance with lipid-lowering
medications; however, the costs and beneﬁts of such 
interventions have not been well studied. We therefore
evaluated the cost-effectiveness of compliance-enhancing
interventions in patients treated with HMG Co-A 
reductase inhibitors (statins). 
METHODS: A literature search was conducted to iden-
tify compliance-enhancing interventions that would be
relevant to statin therapy. A Markov model was used 
to evaluate the programs in a hypothetical cohort of 
5000 statin users 65–84 years of age with myocardial 
infarction. Costs and effectiveness of each strategy were
accrued for the duration of treatment, based on published
studies and the assumption of a linear relationship
between compliance and beneﬁts of therapy. Interven-
tions were evaluated in terms of quality-adjusted life years
gained (QALYs), direct medical costs in U.S. dollars, and
incremental cost-effectiveness (cost per QALY gained). 
RESULTS: Seven compliance-enhancing interventions
were evaluated, including combinations of mailed reﬁll
reminders, unit-of-use (“blister-pack”) prescription 
packaging, telephone counseling by a pharmacist, and
pharmacy or clinic-based drug therapy management. We
found that compared to unaided compliance, these 
strategies would yield an average of 0.20 QALYs, with
cost-effectiveness ratios between $17,700 and $36,600
per QALY gained. When compared incrementally, a 
6-month program consisting of mailed educational 
information, reﬁll reminders and a telephone call from a
pharmacist dominated the other strategies, at $17,700 per
QALY gained, compared to no intervention. When base-
line levels of compliance were lowest, the clinic-based
program was the dominant strategy. 
CONCLUSIONS: Compliance-enhancing interventions
appear to be an attractive way to recover some of the 
clinical beneﬁts that are lost due to noncompliance with
statins. For typical populations, the most cost-effective
intervention provided patient education and reﬁll
reminders via the mail and telephone. Clinical trials 
comparing these interventions should be considered to
conﬁrm these results.
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Patients with congestive heart failure (CHF) often are
treated with amiodarone for ventricular or atrial arrhyth-
mias. This agent is often preferred due to its purported
lack of hemodynamic effects, however other toxicities
may occur. Therefore, routine monitoring of lung,
thyroid, and liver function is recommended. Sanoski CA,
et al previously reported that laboratory tests were 
performed according to accepted guidelines in 23% of
patients before referral to an amiodarone clinic compared
to 90% after referral. 
OBJECTIVE: To establish the role for a formal amio-
darone monitoring program in a multidisciplinary CHF
clinic. 
METHODS: After identifying which patients were taking
amiodarone, a retrospective chart review was used to
determine baseline adherence to national guidelines for
performance of chest x-rays, thyroid and liver function. 
RESULTS: Of the 450 patients in the clinic, 47 were
taking amiodarone. Thirty-two patients were male and 
15 female with an average age of 69 + 13 years (53%
ischemic). Indication for amiodarone therapy: 60% atrial
ﬁbrillation/ﬂutter, 21% ventricular tachycardia, 13%
sudden death, 6% unknown. The chart review period was
18.7 + 16.5 months. Baseline analysis revealed annual
chest x-ray in 42.5% of cases; semiannual thyroid func-
tion in 25%; and semiannual liver function in 40%. Of
the 29 patients still taking amiodarone, 52% did not have
a chest x-ray in the previous 12 months, 52% and 34%
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did not have thyroid or liver function test, respectively in
the previous 6 months. 
CONCLUSIONS: Patient safety from amiodarone toxic
effects is of high concern. Despite national guidelines and
a high prevalence of use, we found that over half of the
patients receiving amiodarone therapy were not being
monitored appropriately for toxicity. We conclude that
there is need for a formal amiodarone monitoring
program in this setting. We have designed and are testing
a chart reminder system to address this deﬁcit.
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OBJECTIVES: Clinical trials have demonstrated that
drug therapy can reduce osteoporosis-related fracture risk
in women over 50 years by up to 40% provided they 
consistently take their medication for a year or more.
Non-adherence with drug therapies not only limits the
drugs’ effectiveness, but could also be associated with a
higher fracture risk. The objective of this study was there-
fore to estimate fracture risk in relation to adherence with
osteoporosis medication in actual practice. 
METHODS: Demographic, prescription drug use, physi-
cian services and hospitalization information for females
with osteoporosis who were dispensed an osteoporosis
medication between 1996 and 2001 (entry date deﬁned
as ﬁrst dispensing in this period) was obtained from the
Saskatchewan Health data ﬁles. Adherence to treatment
was deﬁned as drug available to cover 80% of the time.
Subsequent fractures were identiﬁed via hospitalizations
or physician contacts with a relevant diagnostic or pro-
cedure code. The risk of fractures in relation to adherence
was examined using a Cox proportional hazards model
with time-dependent covariates. The impact of other
patient characteristics, including age, having suffered a
prior fracture, prior use of osteoporosis medication and
steroids, was also examined. 
RESULTS: 11,249 women suffering from osteoporosis
were identiﬁed with a mean age at the time of the index
prescription of 68.4 years and average follow-up of 2.3
years with a fracture rate of 4.5% per year. Patients 
who adhered experienced a 16% lower fracture rate. The
effect of adherence was maintained after controlling for
other patient characteristics that independently predict
the fracture rate, including interactions. 
CONCLUSIONS: These results indicate that improving
adherence in actual practice will signiﬁcantly decrease the
osteoporosis-related fracture risk.
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OBJECTIVES: To investigate under which circumstances
statins can be considered cost-effective in primary 
prevention of CHD, and to identify the most sensitive
parameters. 
METHODS: A Markov Model is used to tackle the
research question for the health insurance and the social
insurance in Germany. Life years gained are chosen as
effectiveness parameter. Mortality is based on the concept
of Gompertzian analysis, linking mortality rates for
persons with and without coronary heart disease (CHD).
Costs components comprise of prevention costs, costs in
the life years gained, national insurance contributions and
avoided costs for CHD-treatment. Age and gender spe-
ciﬁc costs and expenditures for health states are estimated
from data of the social insurance including pension 
payments. CHD-risk estimates are primarily based on
Framingham risk equations, but an alternative method
using current CHD-mortality data is used as well. 
RESULTS: With yearly Statin prices of 300 € (€/$ = .9)
and a relative CHD-risk reduction of 28%, statin treat-
ment for a 50 year old male with a yearly CHD-risk of
1,5% would cost between 23,000 € and 26,000 € per life
year gained for the social insurance and 13,000 € and
16,000 € for the health insurance. For higher CHD-risks
statin treatment gets more cost-effective. At a given value
of CHD-risk, cost-effectiveness is generally better for
younger patients. The most sensitive parameters are the
yearly statin prices und the relative risk reduction. Per 
rise in statin prices of 100 €, cost-effectiveness would
increase between 5,000 € and 7,000 € per life year gained
depending on age and gender. Avoided CHD-treatment
costs, however, have only a minor impact on the 
cost-effectiveness-ratio. 
CONCLUSIONS: Treatment guidelines for CHD preven-
tion incorporating cost-effectiveness considerations are
vulnerable to future statin pricing after the soon fall of
protection by patent. Correct risk estimation remains one
important objective in targeting resources for primary
CHD-prevention.
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The number needed to treat (NNT) has been promoted
as a tool for helping decision makers but valid compari-
